Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
435 Pegasus HNSCC, a platform study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL-2) with anti-cancer agents in patients with recurrent/metastatic head and neck squamous cell carcinoma
Compose a Response to This Article
Other responses
No responses have been published for this article.